Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer

References

• ParkinDMBrayFFerlayJPisaniPGlobal cancer statistics, 2002CA Cancer J Clin20055527410815761078
   PubMed Web of Science ®Google Scholar
• DeVitaVTHellmanJSRosenbergJSCancer Principles and Practice of Oncology7th edPhiladelphiaLippincott Williams & Wilkins2005
   Google Scholar
• KambyCVejborgIKristensenBOlsenLOMouridsenHTMetastatic pattern in recurrent breast cancer. Special reference to intrathoracic recurrencesCancer19886210222622333179937
   PubMed Web of Science ®Google Scholar
• RheeJHanSWOhDYThe clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancerBMC Cancer2008830718947390
   PubMed Web of Science ®Google Scholar
• RiesLAGYoungJLKeelGEEisnerMPLinYDHornerMJSEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988–2001, Patient and Tumor CharacteristicsNIH Publication 07-6215Bethesda, MDNational Cancer Institute2007
   Google Scholar
• MayerELBursteinHJChemotherapy for metastatic breast cancerHematol Oncol Clin North Am200721225727217512448
   PubMed Web of Science ®Google Scholar
• GradisharWJAlbumin-bound paclitaxel: a next-generation taxaneExpert Opin Pharmacother2006781041105316722814
   PubMed Web of Science ®Google Scholar
• GradisharWJTjulandinSDavidsonNPhase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancerJ Clin Oncol200523317794780316172456
   PubMed Web of Science ®Google Scholar
• HendersonICBhatiaVNab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacyExpert Rev Anticancer Ther20077791994317627452
   PubMed Web of Science ®Google Scholar
• PinderMCIbrahimNKNanoparticle albumin-bound paclitaxel for treatment of metastatic breast cancerDrugs Today (Barc)200642959960417028669
   PubMed Web of Science ®Google Scholar
• DesaiNTrieuVYaoZIncreased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxelClin Cancer Res20061241317132416489089
   PubMed Web of Science ®Google Scholar
• NymanDWCampbellKJHershEPhase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignanciesJ Clin Oncol200523317785779316258082
   PubMed Web of Science ®Google Scholar
• BlumJLSavinMAEdelmanGPhase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanesClin Breast Cancer200771185085618269774
   PubMed Web of Science ®Google Scholar
• GradisharWJKrasnojonDCheporovSSignificantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancerJ Clin Oncol200927223611361919470941
   PubMed Web of Science ®Google Scholar
• EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer200945222824719097774
   PubMed Web of Science ®Google Scholar
• OkenMMCreechRHTormeyDCToxicity and response criteria of the Eastern Cooperative Oncology GroupAm J Clin Oncol1982566496557165009
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.org [homepage on the Internet]A Combination of Abraxane and Cisplatin in Metastatic Breast Cancer Available from: http://clinicaltrials.gov/show/NCT01149798
   Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) Version 4.05282009 Revised version 4.03 June 14, 2010National Cancer Institute, National Institutes of Health, US Department of Health and Human Services (Vol. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf)
   Google Scholar
• SimonROptimal two-stage designs for phase II clinical trialsControl Clin Trials19891011102702835
   PubMedGoogle Scholar
• TangLCWangBYSunSHigher rate of skin rash in a phase II trial with weekly nanoparticle albumin-bound paclitaxel and cisplatin combination in Chinese breast cancer patientsBMC Cancer201313123223659317
   PubMedGoogle Scholar
• YamamotoYKawanoIIwaseHNab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approvalOnco Targets Ther2011412313621792318
   PubMed Web of Science ®Google Scholar
• CrownJPegramMPlatinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapyBreast Cancer Res Treat200379Suppl 1S11S1812868801
   PubMedGoogle Scholar
• LoboCLopesGBaezOFinal results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancerBreast Cancer Res Treat2010123242743520585851
   PubMed Web of Science ®Google Scholar
• ConlinAKSeidmanADBachAPhase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancerClin Breast Cancer201010428128720705560
   PubMed Web of Science ®Google Scholar
• RoyVLaPlantBRGrossGGBaneCLPalmieriFMNorth Central Cancer Treatment GroupPhase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531)Ann Oncol200920344945319087987
   PubMed Web of Science ®Google Scholar
• O’ShaughnessyJMilesDVukeljaSSuperior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial resultsJ Clin Oncol200220122812282312065558
   PubMed Web of Science ®Google Scholar
• AlbainKSNagSMCalderillo-RuizGGemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatmentJ Clin Oncol200826243950395718711184
   PubMed Web of Science ®Google Scholar
• MillerKWangMGralowJPaclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerN Engl J Med2007357262666267618160686
   PubMed Web of Science ®Google Scholar
• MilesDWChanADirixLYPhase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancerJ Clin Oncol201028203239324720498403
   PubMed Web of Science ®Google Scholar
• SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med20013441178379211248153
   PubMed Web of Science ®Google Scholar
• WardleyAMPivotXMorales-VasquezFRandomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancerJ Clin Oncol201028697698320038734
   PubMed Web of Science ®Google Scholar
• JonesSEMetastatic breast cancer: the treatment challengeClin Breast Cancer20088322423318650152
   PubMed Web of Science ®Google Scholar
• GuoXLoiblSUntchMRe-challenging taxanes in recurrent breast cancer in patients treated with (neo-)adjuvant taxane-based therapyBreast Care (Basel)20116427928322164126
   PubMed Web of Science ®Google Scholar
• PalmieriCJonesAThe 2011 EBCTCG polychemotherapy overviewLancet2012379981439039222152852
   PubMed Web of Science ®Google Scholar
• DansoMABlumJLRobertNJPhase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer [abstract]J Clin Oncol200826 (ASCO Annual Meeting Proceedings): Abstract 1075
   Google Scholar
• MirtschingBCosgriffTHarkerGKeatonMChidiacTMinMA phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancerClin Breast Cancer201111212112821569998
   PubMed Web of Science ®Google Scholar
• RugoHSBarryWTMoreno-AspitiaACALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC) [abstract]J Clin Oncol201230CRA1002
   Web of Science ®Google Scholar
• SocinskiMALangerCJOkamotoISafety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancerAnn Oncol201324231432123123509
   PubMed Web of Science ®Google Scholar